MA51189A - Conjugués d'inhibiteur de la voie de récupération du nicotinamide adénine dinucléotide quaternarisé - Google Patents
Conjugués d'inhibiteur de la voie de récupération du nicotinamide adénine dinucléotide quaternariséInfo
- Publication number
- MA51189A MA51189A MA051189A MA51189A MA51189A MA 51189 A MA51189 A MA 51189A MA 051189 A MA051189 A MA 051189A MA 51189 A MA51189 A MA 51189A MA 51189 A MA51189 A MA 51189A
- Authority
- MA
- Morocco
- Prior art keywords
- quaternarized
- adenine dinucleotide
- nicotinamide adenine
- recovery route
- inhibitor conjugates
- Prior art date
Links
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229950006238 nadide Drugs 0.000 title 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 title 1
- 238000011084 recovery Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762490733P | 2017-04-27 | 2017-04-27 | |
US201762573987P | 2017-10-18 | 2017-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA51189A true MA51189A (fr) | 2020-03-04 |
Family
ID=62165714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051189A MA51189A (fr) | 2017-04-27 | 2018-04-27 | Conjugués d'inhibiteur de la voie de récupération du nicotinamide adénine dinucléotide quaternarisé |
Country Status (14)
Country | Link |
---|---|
US (2) | US11931414B2 (fr) |
EP (1) | EP3615081A1 (fr) |
JP (2) | JP7425606B2 (fr) |
KR (1) | KR20190141181A (fr) |
CN (1) | CN110799217A (fr) |
AU (2) | AU2018258687C1 (fr) |
BR (1) | BR112019022445A2 (fr) |
CA (1) | CA3060206A1 (fr) |
IL (1) | IL269794A (fr) |
MA (1) | MA51189A (fr) |
MX (2) | MX2019012194A (fr) |
SG (1) | SG11201909563VA (fr) |
TW (1) | TW201904613A (fr) |
WO (1) | WO2018201087A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019001945A2 (pt) | 2016-08-09 | 2019-05-07 | Seattle Genetics, Inc. | composição de conjugado de fármaco aglutinante, formulação farmaceuticamente aceitável, métodos para tratar uma doença ou afecção hiperproliferativa, para inibir a multiplicação de uma célula tumoral ou célula cancerígena e para preparar uma composição de conjugado de fármaco aglutinado, e, composto |
EP3528850A4 (fr) | 2016-10-18 | 2020-06-24 | Seattle Genetics, Inc. | Administration ciblée d'inhibiteurs de la voie de récupération de nicotinamide adénine dinucléotide |
CA3060206A1 (fr) | 2017-04-27 | 2018-11-01 | Seattle Genetics, Inc. | Conjugues d'inhibiteur de la voie de recuperation du nicotinamide adenine dinucleotide quaternarise |
CN110339181A (zh) * | 2019-07-02 | 2019-10-18 | 中国药科大学 | 一种基于点击反应的pH响应型纳米制剂及其制法和应用 |
CN111454327B (zh) * | 2020-04-02 | 2024-07-26 | 中国人民解放军第二军医大学 | 一种nampt蛋白降解靶向嵌合体及其制备方法和应用 |
WO2021207701A1 (fr) * | 2020-04-10 | 2021-10-14 | Seagen Inc. | Lieurs de variants de charge |
WO2024052685A1 (fr) | 2022-09-09 | 2024-03-14 | MyricX Pharma Limited | Composés imidazo[1,2-a]pyridine cytotoxiques et leur utilisation en thérapie |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2036891B (en) | 1978-12-05 | 1983-05-05 | Windsor Smith C | Change speed gear |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (fr) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Récepteurs chimériques par liaison et expression de l'ADN |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
WO1997034631A1 (fr) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Domaines analogues a l'immunoglobuline a demi-vies prolongees |
US6451816B1 (en) | 1997-06-20 | 2002-09-17 | Klinge Pharma Gmbh | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression |
DE19624668A1 (de) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
GB9711125D0 (en) | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
WO2000061559A1 (fr) | 1999-04-09 | 2000-10-19 | Shionogi Bioresearch Corp. | Composes de cyanoguanidine n-substitues |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
KR20040111626A (ko) * | 2002-05-17 | 2004-12-31 | 레오 파마 에이/에스 | 시아노구아니딘 전구약물 |
AU2003263964C1 (en) | 2002-07-31 | 2010-08-19 | Seagen Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
ES2579836T3 (es) | 2003-11-06 | 2016-08-17 | Seattle Genetics, Inc. | Compuestos de monometilvalina capaces de conjugación con ligandos |
AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
US8871720B2 (en) | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
EP3498289A1 (fr) | 2005-07-07 | 2019-06-19 | Seattle Genetics, Inc. | Composés de monométhylvaline présentant des modifications de la chaîne latérale de phénylalanine au niveau de la terminaison c |
US20080279868A1 (en) | 2005-09-26 | 2008-11-13 | Medarex, Inc. | Antibody-Drug Conjugates and Methods of Use |
US8257706B2 (en) | 2006-08-25 | 2012-09-04 | Seattle Genetics, Inc. | CD30 binding agents and uses thereof |
US7968687B2 (en) | 2007-10-19 | 2011-06-28 | Seattle Genetics, Inc. | CD19 binding agents and uses thereof |
WO2009086835A1 (fr) | 2008-01-11 | 2009-07-16 | Topotarget A/S | Nouvelles cyanoguanidines |
EP2240495B1 (fr) | 2008-02-01 | 2015-07-15 | Genentech, Inc. | Métabolite de némorubicine et réactifs analogues, conjugués anticorps-médicament et procédés |
MY157165A (en) | 2008-04-30 | 2016-05-13 | Immunogen Inc | Cross-linkers and their uses |
US8324165B2 (en) | 2008-05-14 | 2012-12-04 | Five Prime Therapeutics, Inc. | Compositions for treating arthritis comprising HG1023575 polypeptide |
MX2010014310A (es) | 2008-06-24 | 2011-02-15 | Topotarget As | Derivados de acido escuarico como inhibidores de la nicotinamida. |
AU2009286604B2 (en) | 2008-08-29 | 2015-05-28 | Onxeo Dk, Branch Of Onxeo S.A., France | Novel urea and thiourea derivatives |
US20120264755A1 (en) | 2009-06-09 | 2012-10-18 | TopoTarget | Pyridinyl derivatives as inhibitors of enzyme nicotinamide phosphoribosyltransferase |
WO2011006988A1 (fr) * | 2009-07-17 | 2011-01-20 | Topotarget A/S | Procédé de prédiction de lutilité de ladministration dacide nicotinique ou dun précurseur ou dun pro-médicament de lacide nicotinique pour réduire la gravité des effets secondaires dun traitement anticancéreux à base dinhibiteurs de nicotinamide phosphoribosyltransférase |
RU2617988C2 (ru) | 2010-09-03 | 2017-05-02 | ФОРМА ТиЭм, ЭлЭлСИ | Новые соединения и композиции для ингибирования nampt |
BR112013004858A8 (pt) | 2010-09-03 | 2018-01-02 | Forma Tm Llc | derivados de 4-{[(piridin-3-il-metil) aminocarbonil]amino}benzeno-sulfona como inibidores de nampt para terapia de doenças tal como câncer |
EP2640698A1 (fr) | 2010-11-15 | 2013-09-25 | AbbVie Inc. | Inhibiteurs de nampt et rock |
EP2640704A1 (fr) | 2010-11-15 | 2013-09-25 | Abbvie Inc. | Inhibiteurs de nampt |
KR101993921B1 (ko) | 2010-12-06 | 2019-06-28 | 시애틀 지네틱스, 인크. | Liv-1에 대한 인간화 항체 및 이의 암을 치료하기 위한 용도 |
TW201245152A (en) | 2011-05-04 | 2012-11-16 | Forma Tm Llc | Novel compounds and compositions for the inhibition of NAMPT |
AU2011367809B2 (en) | 2011-05-09 | 2017-04-27 | Forma Tm, Llc | Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) |
CN103929961A (zh) | 2011-06-20 | 2014-07-16 | 美国阿尔茨海默病研究所公司 | 化合物及其治疗应用 |
MX348311B (es) | 2011-11-11 | 2017-06-06 | Abbvie Inc | Inhibidores nampt. |
WO2013082150A1 (fr) | 2011-11-30 | 2013-06-06 | The Curators Of The University Of Missouri | Inhibiteurs à petite molécule de nicotinamide phosphoribosyltransférase (nampt) |
WO2013123152A2 (fr) | 2012-02-17 | 2013-08-22 | Seattle Genetics, Inc. | Anticorps dirigés contre l'intégrine αvβ6 et leur utilisation pour le traitement du cancer |
WO2013130935A1 (fr) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Dérivés sulfoxydes amido-benzyliques |
WO2013127268A1 (fr) | 2012-03-02 | 2013-09-06 | Genentech,Inc. | Dérivés sulfonamides et sulfones amido-benzyliques |
WO2013130943A1 (fr) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Dérivés sulfonamides amido-benzyliques substitués par un groupe alkyle et disubstitués |
CA2873075A1 (fr) | 2012-05-11 | 2013-07-14 | Abbvie Inc. | Inhibiteurs de nampt |
WO2013170118A1 (fr) | 2012-05-11 | 2013-11-14 | Abbvie Inc. | Dérivés de thiazolecarboxamide utiles en tant qu'inhibiteurs de la nampt |
WO2013170191A1 (fr) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Procédés d'utilisation d'antagonistes de biosynthèse de nicotinamide adénine dinucléotide à partir de nicotinamide |
CN104428301A (zh) | 2012-05-11 | 2015-03-18 | 艾伯维公司 | Nampt抑制剂 |
EP2847181A1 (fr) | 2012-05-11 | 2015-03-18 | AbbVie Inc. | Dérivés de pyridazine et pyridine en tant qu'inhibiteurs de nampt |
US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
PL2917195T3 (pl) | 2012-11-05 | 2018-04-30 | Pfizer Inc. | Analogi spliceostatyny |
WO2014074715A1 (fr) | 2012-11-07 | 2014-05-15 | Genentech, Inc. | Dérivés d'amide cyclopropyle |
WO2014111871A1 (fr) | 2013-01-17 | 2014-07-24 | Aurigene Discovery Technologies Limited | Dérivés de 4,5-dihydroisoxazole utilisés comme inhibiteurs de nampt |
ITTO20130356A1 (it) | 2013-05-03 | 2014-11-04 | Uni Degli Studi Del Piemonte Orientale Ame | Inibitori di nicotinamide fosforibosil transferasi, relative composizioni, prodotti ed usi |
JP2016532648A (ja) | 2013-10-09 | 2016-10-20 | イーライ リリー アンド カンパニー | Nampt阻害剤として有用な新規ピリジルオキシアセチルテトラヒドロイソキノリン化合物 |
HUE051389T2 (hu) * | 2013-10-15 | 2021-03-01 | Seagen Inc | Pegilezett gyógyszer-linkerek ligandum-gyógyszer konjugátum javított farmakokinetikájához |
KR20220127364A (ko) | 2013-12-19 | 2022-09-19 | 씨젠 인크. | 표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커 |
TW201625578A (zh) | 2014-04-18 | 2016-07-16 | 千禧製藥公司 | 喹啉化合物及其用途 |
TW201625641A (zh) | 2014-05-22 | 2016-07-16 | 健臻公司 | Nampt抑制劑及方法 |
CA2954328A1 (fr) | 2014-07-23 | 2016-01-28 | Aurigene Discovery Technologies Limited | Derives de 4,5-dihydroisoxazole comme inhibiteurs de nampt |
SG10202006505UA (en) | 2014-09-11 | 2020-08-28 | Seattle Genetics Inc | Targeted delivery of tertiary amine-containing drug substances |
CN104557863B (zh) | 2014-12-18 | 2017-03-15 | 中国科学院广州生物医药与健康研究院 | 一种新型烟酰胺磷酸核糖转移酶抑制剂及其合成方法与应用 |
EP3247705B1 (fr) | 2015-01-20 | 2019-11-20 | Millennium Pharmaceuticals, Inc. | Composés quinazoline et quinoléine, et utilisations de ceux-ci en tant qu'inhibiteurs nampt |
EP3528850A4 (fr) | 2016-10-18 | 2020-06-24 | Seattle Genetics, Inc. | Administration ciblée d'inhibiteurs de la voie de récupération de nicotinamide adénine dinucléotide |
CA3060206A1 (fr) | 2017-04-27 | 2018-11-01 | Seattle Genetics, Inc. | Conjugues d'inhibiteur de la voie de recuperation du nicotinamide adenine dinucleotide quaternarise |
-
2018
- 2018-04-27 CA CA3060206A patent/CA3060206A1/fr active Pending
- 2018-04-27 KR KR1020197033551A patent/KR20190141181A/ko not_active Application Discontinuation
- 2018-04-27 CN CN201880042426.XA patent/CN110799217A/zh active Pending
- 2018-04-27 JP JP2019555959A patent/JP7425606B2/ja active Active
- 2018-04-27 MA MA051189A patent/MA51189A/fr unknown
- 2018-04-27 AU AU2018258687A patent/AU2018258687C1/en active Active
- 2018-04-27 TW TW107114520A patent/TW201904613A/zh unknown
- 2018-04-27 BR BR112019022445-9A patent/BR112019022445A2/pt active Search and Examination
- 2018-04-27 SG SG11201909563V patent/SG11201909563VA/en unknown
- 2018-04-27 US US16/608,748 patent/US11931414B2/en active Active
- 2018-04-27 WO PCT/US2018/030018 patent/WO2018201087A1/fr unknown
- 2018-04-27 MX MX2019012194A patent/MX2019012194A/es unknown
- 2018-04-27 EP EP18724738.2A patent/EP3615081A1/fr active Pending
-
2019
- 2019-10-03 IL IL26979419A patent/IL269794A/en unknown
- 2019-10-10 MX MX2023014831A patent/MX2023014831A/es unknown
-
2022
- 2022-10-05 AU AU2022246407A patent/AU2022246407B2/en not_active Withdrawn - After Issue
-
2023
- 2023-07-10 JP JP2023113358A patent/JP2023119064A/ja active Pending
-
2024
- 2024-01-16 US US18/414,104 patent/US20240293554A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110799217A (zh) | 2020-02-14 |
BR112019022445A2 (pt) | 2020-05-12 |
US11931414B2 (en) | 2024-03-19 |
AU2018258687B2 (en) | 2022-07-07 |
TW201904613A (zh) | 2019-02-01 |
JP7425606B2 (ja) | 2024-01-31 |
SG11201909563VA (en) | 2019-11-28 |
CA3060206A1 (fr) | 2018-11-01 |
EP3615081A1 (fr) | 2020-03-04 |
AU2018258687A1 (en) | 2019-12-05 |
US20240293554A1 (en) | 2024-09-05 |
KR20190141181A (ko) | 2019-12-23 |
IL269794A (en) | 2019-11-28 |
AU2022246407A1 (en) | 2022-11-17 |
US20200197524A1 (en) | 2020-06-25 |
MX2023014831A (es) | 2024-01-15 |
AU2018258687C1 (en) | 2023-02-02 |
JP2023119064A (ja) | 2023-08-25 |
MX2019012194A (es) | 2019-12-16 |
JP2020517599A (ja) | 2020-06-18 |
AU2022246407B2 (en) | 2024-07-18 |
WO2018201087A1 (fr) | 2018-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA51189A (fr) | Conjugués d'inhibiteur de la voie de récupération du nicotinamide adénine dinucléotide quaternarisé | |
MA46660A (fr) | Administration ciblée d'inhibiteurs de la voie de récupération de nicotinamide adénine dinucléotide | |
MA49421A (fr) | Formulations d'arn | |
DK3532607T3 (da) | Restimulation af kryokonserverede, tumorinfiltrerende lymfocytter | |
MA47606A (fr) | Procédés de purification d'arn messager | |
MA43417A (fr) | Agonistes améliorés du récepteur de l'apéline (apj) et leurs utilisations | |
MA50456A (fr) | Formulations d'un inhibiteur de kinase trk macrocyclique | |
IT201700070755A1 (it) | “sistema di separazione” | |
DK2861608T3 (da) | Prodrug-derivater af (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamid | |
MA54688A (fr) | Nébuliseur d'aérosol aseptique | |
MA49006A (fr) | Inhibiteurs d'ip6k | |
DK3576719T3 (da) | Misbrugsafskrækkende formuleringer på basis af amfetamin | |
MA51285A (fr) | Dérivés d'azaindole comme inhibiteurs de rho-kinase | |
MA48442A (fr) | Structure d'extérieur | |
DK3271036T3 (da) | Vandrutschebane og vandrutschebanesystem | |
ES1185433Y (es) | Pantalon de entrenamiento | |
IT201600095893A1 (it) | Metodo per implementare realta' aumentata | |
MA49044A (fr) | Nicotinamide à libération modifiée | |
DK3515454T3 (da) | Krystallinsk polymorf form af 3-hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-oxo-2lambda5-[1,2]oxaphosphinan | |
MA43764A (fr) | Inhibiteur monovalent de l'interaction hutnfr1 | |
FR3032870B1 (fr) | Structure de mobilier repliable, en particulier de mobilier d'enseignement | |
GB201721062D0 (en) | CYB route finding | |
ES1206593Y (es) | Dron de levitacion magnetica | |
ITUB20153493A1 (it) | Attrezzatura per l'applicazione di borchie. | |
IT201700033998A1 (it) | Sistema d'arredo a incastri multipli |